Glypican-1 (GPC-1) was selected as the biomarker for identifying collected tumor cells, and the microfluidic device proved to be functional in capturing GPC1+ putative tumor cells; moreover, the number of captured GPC1+ cells was found to be correlated with the Gleason score used in grading prostate cancer. This evidence concerns the gene GPC1 and prostate carcinoma.